Reem Alsherooqi

Reem Alsherooqi

Auto-generated profile, based on publicly available information

Reem Alsherooqi

Family Medicine Ministry of Health Manama Bahrain

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 February 2021 in eJHaem
Verified
Journal Article
Open access
PDF file
AAAbdulkarim Abdulrahman
Abdulkarim Abdulrahman
MMMohamed Wael Mohamed
Mohamed Wael Mohamed
FAFajer AlAmmadi
Fajer AlAmmadi
ZAZahra Almosawi
Zahra Almosawi
RAReem Alsherooqi
Reem Alsherooqi
Manaf Al-QahtaniManaf Al-Qahtani
Manaf Al-Qahtani
Introduction: Studies that examine the association between sickle cell disease (SCD) and COVID‐19 outcomes are lacking. This study aims to determine whether SCD is a risk factor for severe COVID‐19 infection in regard to the requirement of noninvasive ventilation/high flow nasal cannula (NIV/HFNC), mechanical ventilation (MV), or death in hospitalized patients.Methods: Retrospective cohort study included COVID‐19 patients admitted to four COVID‐19 treatment facilities in Bahrain between February 24, 2020 and July 31, 2020. All SCD patients with COVID‐19 were included and compared to a randomly selected sample of non‐SCD patients with COVID‐19. Data were collected from the medical records. Multivariate logistic regression models were used to control for confounders and estimate the effect of SCD on the outcomes.Results: 1792 patients with COVID‐19 were included; 38 of whom were diagnosed with SCD as well. In the SCD group, one (2.6%) patient required NIV/HFNC, one (2.6%) required MV, and one (2.6%) death occurred. In comparison, 56 (3.2%) of the non‐SCD patients required NIV/HFNC, 47 (2.7%) required MV, and death occurred in 58 (3.3%) patients. Upon adjusting for confounders, SCD had an odds ratio of 1.847 (95% CI: 0.39–8.83; p = 0.442).Conclusion: Our results indicate that SCD is not a risk factor for worse COVID‐19 outcomes in hospitalized patients.

4 January 2021 in medRxiv
Verified
Preprint
Open access
PDF file
AAAbdulkarim Abdulrahman
Abdulkarim Abdulrahman
MMMohamed Wael Mohamed
Mohamed Wael Mohamed
FAFajer AlAmmadi
Fajer AlAmmadi
ZAZahra AlMosawi
Zahra AlMosawi
RAReem Alsherooqi
Reem Alsherooqi
Manaf Al-QahtaniManaf Al-Qahtani
Manaf Al-Qahtani
Introduction Coronavirus disease (COVID-19) caused by the novel coronavirus SARS-CoV-2 is an infectious disease which has evolved into a worldwide pandemic. Growing evidence suggests that individuals with pre-existing comorbidities are at higher risk of a more serious COVID-19 illness. Sickle cell disease (SCD) is an inherited hemoglobinopathy which increases the susceptibility to infections and as a consequent has higher risks of morbidity and mortality. The impact of COVID-19 on SCD patients could lead to further increase in disease severity and mortality. Studies that examine the effect of SCD on COVID-19 outcomes are lacking. This study aims to determine whether SCD is a risk factor for severe COVID-19 infection in regards to the requirement of non-invasive ventilation/high flow nasal cannula (NIV/HFNC), mechanical intubation (MV) or death. Methods Retrospective cohort study which included COVID-19 patients admitted to four Ministry of Health COVID-19 treatment facilities in Bahrain during the period of 24, February 2020, to 31, July 2020. All SCD patients with COVID-19 were included and compared to randomly selected non-SCD patients with COVID-19. Data for the selected patients were collected from the medical records. Multivariate logistic regression models were used to control for confounders and estimate the effect of SCD on the outcomes. Results A total of 1,792 patients with COVID-19 were included; 38 of whom were diagnosed with SCD as well. In the SCD group, one (2.6%) patient required NIV/HFNC, one (2.6%) required MV and one (2.6%) death occurred. In comparison, 56 (3.2%) of the non-SCD patients required NIV/HFNC, 47 (2.7%) required MV and death occurred in 58 (3.3%) patients. Upon adjusting for confounders, SCD had an odds ratio of 1.847 (95% CI: 0.39 – 8.83; p=0.442). Conclusion Our results indicate that SCD is not a risk factor for worse disease outcomes in COVID-19 patients.